Bedaquiline
- Generic Name
- Bedaquiline
- Brand Names
- Sirturo
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31BrN2O2
- CAS Number
- 843663-66-1
- Unique Ingredient Identifier
- 78846I289Y
- Background
Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhi...
- Indication
Bedaquiline is indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.
...
- Associated Conditions
- Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
- Associated Therapies
- -
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06649721
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Beijing Tsinghua Changgun Hospital, Beijing, Beijing, China
🇨🇳The 8th Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 2530
- Registration Number
- NCT06568484
- Locations
- 🇵🇪
Hipolito Unanue National Hospital, Lima, Peru
🇵🇪SES Policlinico, Lima, Peru
🇿🇦Aurum Tembisa CRS, Tembisa, Gauteng, South Africa
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 690
- Registration Number
- NCT06441006
- Locations
- 🇲🇩
Institute of Phthisiopneumology Chiril Dragniuc, Chisinau, Moldova, Republic of
🇲🇳National Center for Communicable Diseases, Ulaanbaatar, Mongolia
🇵🇪Hospital Nacional Hipólito Unanue, Lima, Peru
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-13
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇺🇬
12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda
🇲🇼30301, Blantyre CRS, Blantyre, Malawi
🇲🇼12001, Malawi CRS, Lilongwe, Malawi
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳Harbin Chest Hospital, Harbin, Heilongjiang, China
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 300
- Registration Number
- NCT06058299
- Locations
- 🇵🇭
Care Clinical Trial Group Inc., Dasmariñas, Philippines
🇬🇪National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
🇵🇭Tropical Disease Foundation, Makati City, Philippines
BTZ-043 Dose Evaluation in Combination and Selection
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 90
- Registration Number
- NCT05926466
- Locations
- 🇹🇿
National Institute for Medical Research (NIMR-Mwanza),, Mwanza, Tanzania
🇿🇦TASK Applied Sciences Clinical Research Centre, Cape Town, South Africa
🇹🇿National Institute for Medical Research (NIMR-MMRC), Mbeya, Tanzania
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Target Recruit Count
- 450
- Registration Number
- NCT05824871
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital affiliated to Capital Medical University, Beijing, Beijing, China
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
A Pan-TB Regimen Targeting Host and Microbe
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- The Aurum Institute NPC
- Target Recruit Count
- 352
- Registration Number
- NCT05686356
- Locations
- 🇲🇿
Instituto Nacional de Saúde, Maputo, Mozambique
🇿🇦Clinical HIV Research Unit, Durban, South Africa
🇿🇦The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.